This article is more than 5 years old. Information may no longer be current.

VIDEO: Early steroids may reduce severe side effects among patients who receive CAR T-cell therapy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Max S. Topp, MD, head of hematology at University Hospital of Wuerzburg, Germany, spoke with HemOnc Today at ASCO Annual Meeting about a study that evaluated the effects of earlier steroid use by patients who underwent chimeric antigen receptor therapy.

The ZUMA-1 trial included patients with relapsed or refractory large B-cell lymphoma treated with axicabtagene ciloleucel (Yescarta, Kite Pharma), an autologous anti-CD19 CAR T-cell therapy.

Data from 21 patients included in a safety expansion cohort showed early use of steroids may help reduce incidence of severe cytokine release syndrome and neurologic events without affecting response rates, Topp said.

The full dataset will be presented in December at ASH Annual Meeting and Exposition, Topp said. – by Mark Leiser

Reference: Topp MS, et al. Abstract 7558. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.

Disclosure: Topp reports consultant/advisory roles with, research funding from, and travel, accommodations or expenses from Amgen, Kite Pharma, Regeneron and Roche.